ASHM Reporters @ CROI 2017

Mike Seah Michael Seah
General Practitioner
Richard Moore Richard Moore
Doctor
Virginia Virginia Furner
Senior HIV Consultant
Wei Pic Wei Cai
General Practitioner
Mark Pic Mark O'Reilly
Doctor
Dr Rob Burton Robert Burton
General Practitioner
Print

ASHM @ CROI 2017

Bloggers

Mike Seah Michael Seah
General Practitioner
Richard Moore Richard Moore
Doctor
Virginia Virginia Furner
Senior HIV Consultant
Wei Pic Wei Cai
General Practitioner
Mark Pic Mark O'Reilly
Doctor
Dr Rob Burton Robert Burton
General Practitioner
                          

 

 

Posts

HEPATITIS C VIRUS: GONE BY 2030?

HEPATITIS C VIRUS: GONE BY 2030? John W. Ward, CDC, Atlanta, GA, USA Recognizing hepatitis C virus (HCV) as a major public health threat, the World

SUBSTANTIAL DECLINE IN ACUTE HCV INFECTIONS AMONG DUTCH HIV+MSM AFTER DAA ROLL OUT

Comment: Abstract follows. Modelling studies presented at CROI in 2016 predicted that prompt treatment of Hepatitis C with direct acting antivirals (

ON DEMAND POST EXPOSURE PROPHYLAXIS WITH DOXYCYCLINE FOR MSM ENROLLED IN A PREP TRIAL

 Comment: Abstract follows. For me, this was one of the most interesting studies presented at CROI this year. It generated much discussion among

Cardiovascular + lung cancer risk and HIV

  A few “Snapshots” from the Inflammation and Age-related Complications session, of interest:   1.       A

VTE and HIV

  Venous thromboembolism (VTE ) risk is increased in HIV patients (5.7 -11.00/1000 person years) compared to the general population (1.0/1000 pe

Third PrEP failure in an adherent individual?

So far there have been two well documented cases of individuals on PrEP contracting HIV despite good adherence and high TDF levels. This poster presen

CNS Treatment Strategies - risks and benefits

I tried something a little different this afternoon. The conference venue set up a simulcast of all concurrent sessions in a theatre-like venue with s

NAFLD and HIV

  Day 3 CROI:   I am sure all the General Practitioners reading this topic are much more familiar with the management of patients with th

Cerebral small vessel disease more common in PLHIV

           Cerebral small-vessel disease (CSVD) is a common problem with increasing age and accounts for approximately 2

Antibiotic prophylaxis for STIs: Promises or Perils

Comment: The significant rise in symptomatic and asymptomatic STIs in recent years is having a huge impact on clinical practice. Many practices strug

PrEP, STI and the microbiome

Wednesday morning featured a series of oral presentations exploring the interplay of STIs and altered microbiomes might affect PrEP. Renee Heffron pr

Site visit to Magnet Clinic- Castro St, San Francisco.

Magnet is a nurse and peer led Sexual Health service in San Francisco. It recently co-located with Strut (San Francisco AIDS Foundation) and a number

Strangers in the Night: STI Control

      Symposium 5-3 ‘Strangers in the Night; Challenges and Opportunities in STI Control: provided a fascinating insight into po

HIV Capsid Inhibitor + Nanoparticle technology

Day 2 CROI My colleagues have already commented on the new HIV integrase strand transfer inhibitor, Bictegravir, so onto other potential new agents/f

Novel new HIV drug - Capsid inhibitor

  Since the advent of integrase inhibitors, bringing about our latest highly effective combination therapy, with viral suppression rat

Weight gain and hepatic steatosis.

Tuesdayy afternoon provided a session of poster presentations exploring the complicated relationship between ARV treatment , excess weight gain and he

Advances in cellular therapy in cancer and HIV

  Dr Carl June presented how novel therapeutics have the potential for an HIV cure. His work in the development of Chimeric Antigen Receptor (CA

Phase III treatment naive study: Doravirine non-inferior to darunavir/r at 48 weeks

Comment: Abstract follows: Doravirine seeks to address the limitations of the currently available NNRTIs: avoidance of neuropsychiatric side effects,

Phase III SWORD 1&2: Switch to DTG+RPV maintains virologic suppression at 48 weeks

Comment: Abstract follows: This study demonstrates non-inferiority of treatment switch to dolutegravir/rilpivirine at 48 weeks versus remaining on cu

Phase II study comparing F/TAF/bictegravir vs F/TAF/dolutegravir

Comment: See abstract below. This phase II study presents non-inferior results and several bictegravir phase III trials in both naïve and switch pati

Tuesday morning at CROI

Hi from Seattle.  Very interesting plenary this morning at 8.30 presented by Jintanat Ananworanich. She spoke about the potential and possible p

The next INSTI on the block?

Greetings from Seattle. I would like to start by thanking ASHM for giving me the opportunity to attend this world-class conference and also thank the

 

Please join us for a memorial event celebrating the life of one of Australia’s leading HIV advocates, Levinia Crook… https://t.co/N7dof5xaGa

ASHM ASHM